The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression.
about
Duloxetine for treating painful neuropathy, chronic pain or fibromyalgiaDuloxetine for treating painful neuropathy or chronic painDuloxetine for treating painful neuropathy or chronic pain5-HT3 receptorsStress-induced changes of hippocampal NMDA receptors: modulation by duloxetine treatmentDuloxetine in the treatment of generalized anxiety disorder.Comparison of neurogenic effects of fluoxetine, duloxetine and running in mice.Inhibition of G protein-activated inwardly rectifying K+ channels by different classes of antidepressants.WAY-318068: a novel, potent and selective noradrenaline re-uptake inhibitor with activity in rodent models of pain and depression.Attributes of response in depressed patients switched to treatment with duloxetine.Duloxetine in the treatment of major psychiatric and neuropathic disorders.Efficacy of Duloxetine in Patients with Chronic Pain ConditionsHealth-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting.Review of Efficacy and Safety of Duloxetine 40 to 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain.Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East AsiaEffects of naltrexone, duloxetine, and a corticotropin-releasing factor type 1 receptor antagonist on binge-like alcohol drinking in rats.Synthesis and structure-activity studies of benzyl ester meperidine and normeperidine derivatives as selective serotonin transporter ligands.Duloxetine in the treatment of major depressive disorder.Enhanced selective serotonin re-uptake inhibitors as antidepressants: 2004 - 2006.Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature.Duloxetine: clinical pharmacokinetics and drug interactions.Neoteric pharmacotherapeutic targets in fibromyalgia.Preclinical discovery of duloxetine for the treatment of depression.A review of duloxetine 60 mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain.A retrospective review of isolated duloxetine-exposure cases.Alleviation of pain in painful diabetic neuropathy.Perspectives in Designing Multifunctional Molecules in Antipsychotic Drug Discovery.The Effect of the Association between Donepezil and Choline Alphoscerate on Behavioral Disturbances in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial.Rapid Management of Trigeminal Neuralgia and Comorbid Major Depressive Disorder With Duloxetine.Antidepressant-like Effects of ZBH2012001, a Novel Potent Serotonin and Norepinephrine Reuptake Inhibitor.Real-world outcomes in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia.An observational study of duloxetine versus SSRI monotherapy for the treatment of painful physical symptoms in Japanese patients with major depressive disorder: primary analysis.Predicting treatment outcomes of major depressive disorder by early improvement in painful physical symptoms: a pooled analysis of double-blind, placebo-controlled trials of duloxetineDuloxetine in the treatment of stress urinary incontinence.Functional Impairment and Painful Physical Symptoms in Patients with Major Depressive Disorder Treated with Antidepressants: Real-World Evidence from the Middle East.Duloxetine in the treatment of burning mouth syndrome refractory to conventional treatment: A case report.Medications for alcohol use disorders: An overview.Pharmacokinetic profiles contribute to the differences in behavioral pharmacology of 071031B enantiomers as novel serotonin and norepinephrine reuptake inhibitors.Duloxetine may enhance control of pain related to bladder trauma.Duloxetine for the treatment of mood disorder in cancer patients: a 12-week case-control clinical trial.
P2860
Q24201220-578394E0-080C-42C8-869D-2F79D2836E3FQ24240634-B7089A16-ACE6-4238-8C34-1BC9B5A3882FQ24243744-D61800AC-CB38-4BB1-AE6A-8988B596A580Q24648000-C6DE2CE1-D6CD-48DF-9DDC-00DCF34B8AEEQ28729135-874FA42E-B4F7-49E3-8A06-45E6C6302053Q33735030-76C499F2-0DBB-4419-BD4B-7A55567703F7Q33907598-321E0979-BC38-4DDA-8AA9-BC4E985EBE0FQ34099069-0C75D76E-E0CD-4FE0-B140-6988A0771048Q34112969-36E81504-C85A-4590-9AEA-F33AD92E2D19Q34474860-653BF197-52CA-468D-A636-09261BC1F4C4Q34770302-BD1694BA-A043-4206-B666-E332EC0E6C7CQ36141335-06E6A960-1CD2-4029-862A-65A2E03623C2Q36208461-BFC3C229-783E-4AB9-80D6-1C391F9A9189Q36220913-9BF8BAA8-FB92-464E-9572-165D87280788Q36627458-D8B9548C-7A9B-428A-ABDF-8EA3953820F0Q36982413-9CC4C091-BDE6-474A-B9AC-46A6A7F2CD72Q37020345-AD84DF0A-344E-4116-B2A0-F5A725092C0FQ37125752-C8C03C9C-D4D0-40D6-A4F5-1654BFD09B60Q37689787-7085F6F1-C455-4DE5-BCD3-AD80718E27CBQ37733559-3A417A25-EDF9-415C-9D82-8BB2382A2144Q37848815-7FDA4A40-3D49-4724-99CD-42B2F40EDE62Q37929796-C0ED31F1-55E6-45C9-9B5C-68686A0C8F21Q38017215-5C28B491-F1D5-483D-9A5C-B673A9391111Q38020236-0A0689C2-0B5F-4425-8D91-06E9A18CF230Q38077304-12FE67F9-6E95-4F19-8B0F-359CDC28FB12Q38826512-8CD919F9-8336-46C7-86C0-4A2307611E56Q38931450-F116E127-C001-4889-99EB-4FF82683D655Q39051115-37780235-40D2-4306-8BC1-3DD06D4E9349Q39207602-C7519989-2033-473D-A7E6-EF90428F4867Q39748512-74270CB0-FA70-47C6-91F9-1DEC9AF6294EQ41161590-77D7D3F0-8298-4F46-8838-DF966F5A964AQ41347942-B35AA264-BA3C-4BA6-8241-306492B6EA84Q42283214-D4F7C488-A7D2-40BF-A7CC-8AF0AB89B997Q43267071-2CB19D81-E05A-4A8C-9EC8-A151AFB85091Q47112259-0392D775-204B-4269-80CB-D7EED9B06D15Q47882285-D6DDE3FC-E3E4-4A74-9814-0212A93DAD12Q47942161-E05A5A7F-D839-4E32-ACC0-141494B5683AQ47958378-2ACA61A7-243C-4AF9-AAC9-E8D212647090Q48330605-7A085F8E-9CD7-4663-862C-79D2415A92D3Q48630921-2109FC8A-DD26-4524-8085-10A93DFF470A
P2860
The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The dual transporter inhibitor ...... linical results in depression.
@ast
The dual transporter inhibitor ...... linical results in depression.
@en
type
label
The dual transporter inhibitor ...... linical results in depression.
@ast
The dual transporter inhibitor ...... linical results in depression.
@en
prefLabel
The dual transporter inhibitor ...... linical results in depression.
@ast
The dual transporter inhibitor ...... linical results in depression.
@en
P2093
P356
P1476
The dual transporter inhibitor ...... linical results in depression.
@en
P2093
Frank P Bymaster
Mary Pat Knadler
Michael J Detke
Smriti Iyengar
Thomas C Lee
P304
P356
10.2174/1381612053764805
P577
2005-01-01T00:00:00Z